Structure and antibacterial activities of new cyclic peptide antibiotics, pargamicins B, C and D, from Amycolatopsis sp. ML1-hF4

Journal of Antibiotics

Volumn 70, Issue 5, 2017, Pages 699-704

  Hashizume, Hideki ^a   Sawa, Ryuichi ^a   Yamashita, Kazuma ^a   Nishimura, Yoshio ^a   Igarashi, Masayuki ^a  

^a INSTITUTE OF MICROBIAL CHEMISTRY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPEPTIDE; HYDROXYL GROUP; PARGAMICIN A; PARGAMICIN B; PARGAMICIN C; PARGAMICIN D; UNCLASSIFIED DRUG; VANCOMYCIN;

AMYCOLATOPSIS; AMYCOLATOPSIS SP ML1 HF4; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIUM CULTURE; DRUG ISOLATION; DRUG STRUCTURE; ENTEROCOCCUS; FERMENTATION; GRAM POSITIVE BACTERIUM; HETERONUCLEAR MULTIPLE BOND CORRELATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STAPHYLOCOCCUS; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ACTINOMYCETALES; CHEMISTRY; DRUG EFFECT; ISOLATION AND PURIFICATION; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST;

ACTINOMYCETALES; ANTI-BACTERIAL AGENTS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; STRUCTURE-ACTIVITY RELATIONSHIP; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 85019544289     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2017.34     Document Type: Article

References (13)

1. Tom, F. Antibiotic Resistance Threats in the United States, 2013 (Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, 2013).
2. Linsay, M. The Evolving Threat of Antimicrobial Resistance-Options for Action (World Health Organization, 2012).
3. Hilary, C. & Lindsay, M. Antimicrobial Resistance Global Report on Surveillance. 2014 (World Health Organization, 2014).
4. Werner,G. et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro. Surveil. 13, 1-11 (2008).
5. Deshpande, L. M. et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58, 163-170 (2007).
6. Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P. & Grayson, M. L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23, 99-139 (2010).
7. Moravvej, Z. et al. Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains. Int. J. Antimicrob. Agents 42, 370-371 (2013).
8. Igarashi, M. et al. Pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp. J. Antibiot. 61, 387-393 (2008).
9. Hashizume, H., Adachi, H., Igarashi, M., Nishimura, Y. & Akamatsu, Y. Biological activities of pargamicin A, a novel cyclic peptide antibiotic from Amycolatopsis sp. J. Antibiot. 63, 279-283 (2010).
10. Silverman, J. A., Perlmutter, N. G. & Shapiro, H. M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 2538-2544 (2003).
11. Harada, K. et al. Application of D, L-FDLA derivatization to determination of absolute configulation of constituent amino acids in peptide by advanced Marfey's method. Tetrahedron Lett. 37, 3001-3004 (1996).
12. Oh, D.-C., Poulsen, M., Currie, C. R. & Clardy, J. Dentigerumycin: a bacterial mediator of an ant-fungus symbiosis. Nat. Chem. Biol. 5, 391-393 (2009).
13. Japan Society of Chemotherapy. Method of MIC determination. Chemotherapy 29, 77-79 (1981).